U.S. Tariffs on India’s pharma: Who pays, what’s at risk
The structural answer to tariff risk is not endless cost-cutting; it is moving up the value chain
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Guest Blogs
Can we reduce plastics usage in pharmaceutical industry? – Think
Dr Ashok Omray highlights the widespread use of single-use plastics in pharma manufacturing and calls for scientific solutions to…
U.S. trade policy is jeopardising the U.S. – India pharma supply chain
Ankit Shrivastava explains how escalating tariffs may threaten generic drug access, increase costs for American patients, and…
Why India’s B.Pharm graduates need a standardised National Exit Exam
Dr Akram Ahmad, CEO & Founder, Academically Global, says that while India leads in pharma manufacturing and exports,…
Enhancing visibility, predictability and transparency in IP procedures
Milind Sathe, Vice President -IP and Tech, Themis Medicare, explains how certain robust search and tracking facilities can enhance…
Rethinking trust: what pharma can learn from Indian corner shops
Anagha Shirur - Adjunct Faculty, K J Somaiya Institute of Management, expresses how lessons from the kirana shops may offer…
Beauty, boosters and the law: Who’s watching India’s wellness market?
Biplab Lenin, Partner; and Anam Chowdhary, Associate, Cyril Amarchand Mangaldas, stress that regulatory vigilance on the…
Hyderabad: Accelerating the future of life sciences
Anshuman Magazine, Chairman & CEO – India, South-East Asia, Middle East & Africa, CBRE, highlights Hyderabad’s growing…
Why most extractables & leachables studies fail regulatory review-and how to fix them
Madhu of SG Pharma Solutions highlights why extractables and leachables (E&L) studies frequently fail regulatory review and…
Addressing US FDA challenges in Indian sterile drug manufacturing – Part 3
In this final instalment, Manish Bhatkar, Founder & CEO, RedLotus Pharmtech, transitions from analysis to action. Drawing on…
Addressing US FDA challenges in Indian sterile drug manufacturing – Part 2
In this second part, Manish Bhatkar, Founder & CEO, RedLotus Pharmtech continues the discussion on FDA expectations, with…
Addressing US FDA challenges in Indian sterile drug manufacturing – Part 1
In the three-part series, Manish Bhatkar, Founder & CEO, RedLotus Pharmtech in this article explores the evolution of India’s…
Driving change: Digital innovation and the future of drug discovery in India
Dr Trupti Kad-Shinde, Senior member, Medical Research and content team, ImmersiveVision Technology and Dr Debashree Das,…
Role of nitric oxide in controlling genetic regulators to maintain cellular health
Prof Syamantak Majumder, Prof Sandeep Sundriyal, and Prof Shibasish Chowdhury, researchers at BITS Pilani, reveal how nitric oxide…
Small benefits, big impact: Understanding the value of novel drugs in metastatic cancer
Dr Jahnavi Pedireddy, Medical Oncology Trainee, Apollo Hospitals, Bengaluru; Dr Narendhar Gokulanathan, Medical Oncology Trainee,…
Pharma and medtech marketing: Navigating the imminent disclosure deadline
Kunal Gupta, Partner, White-Collar Crime Practice and Sahil Bansal, Counsel - White-Collar Crime Practice, Trilegal stress that…
7 common compliance issues faced by the pharmaceutical industry in India
Mahesh Krishnamoorthy, Managing Director, Core Integra stresses that compliance in pharma is non-negotiable; highlights seven key…
Navigating geopolitical shifts: India’s strategic position in global pharma supply chains
Rakesh Gupta, Managing Partner, LoEstro Advisors, explains that speed, quality, and transparency will be the key differentiators…
Three factors to make a next-gen eCOA platform work
Melissa Mooney, Director, eCOA Solutions Engineering, IQVIA, emphasises that as timelines tighten, regulatory scrutiny…
A defining opportunity for clarity from GS1
Avi Chaudhuri, PhD - Founder, The Kulinda Consortium, presents a set of assertions made about counterfeit medicines problem along…